Premium
Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry
Author(s) -
Doobaree Indraraj Umesh,
Newland Adrian,
McDonald Vickie,
Nandigam Raghava,
Mensah Lesley,
Leroy Sandrine,
Seesaghur Anouchka,
Patel Hitan,
Wetten Sally,
Provan Drew
Publication year - 2019
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13221
Subject(s) - romiplostim , medicine , splenectomy , thrombopoietin , eltrombopag , immune thrombocytopenia , refractory (planetary science) , cohort , pediatrics , platelet , genetics , stem cell , haematopoiesis , biology , spleen , physics , astrobiology
Abstract Background Romiplostim is a thrombopoietin‐mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice. Methods This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6 months before romiplostim initiation through follow‐up. Results Of 1440 patients in the UKITP Registry, 118 adults with primary ITP were eligible. Before romiplostim, 22% had splenectomy, 12% received platelet transfusion, 97% received ≥ 1 different ITP medication and 77% received ≥ 3. Most patients (73%) initiated romiplostim ≥ 1 year after ITP diagnosis (chronic phase). The mean duration of romiplostim treatment was 5.7 (SE 0.9) months, and the median was 1.4 months (IQR: 0.2, 6.5). Mean platelet count before romiplostim was 38 × 10 9 /L, rising to 103 × 10 9 /L within 1 month, and remaining 50‐150 × 10 9 /L through up to 3 years of follow‐up. After romiplostim, 4% of patients had splenectomy, 6% received platelet transfusion, and 57% received just one ITP medication other than romiplostim. Conclusion The study provides valuable insights into the real‐world use of romiplostim in primary ITP in routine practice and highlighted the timing of romiplostim initiation at different ITP disease phases.